Loading
companiesCompany
Xuanzhu Biopharmaceutical
Xuanzhu Biopharmaceutical is a China-based biotechnology company running 3 late-stage cancer trials of XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer.
Also called: Xuanzhu Biopharmaceutical Co., Ltd.
Overview
Xuanzhu Biopharmaceutical, based in Beijing, China, is a biotechnology company. Xuanzhu Biopharmaceutical is a China-based biopharmaceutical company developing drugs for digestive system diseases, oncology and NASH (non-alcoholic fatty liver disease). On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer. The largest, NCT05257395 (A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer), plans to enrol 397 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Beijing, CN
Scorecard
All companies#433of 1244 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Website
Founded
2008
Phase 3small molecule
XZP-3287 is an experimental small-molecule drug from Sihuan Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
Similar pages
- TreatmentAnastrozole
Shares A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer, HR-positive / HER2-negative breast cancer.
- CancerNTRK fusion-positive non-small-cell lung cancer
Shares A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors, Non-small-cell lung cancer.
cancers
drugs
Phase 3small molecule
trials
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerA Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerA Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors